Henan Shengming Biotechnology

Henan Shengming Biotechnology Research Institute Co., Ltd. (also operating as Shengming Biotechnology (Zhengzhou) Co., Ltd.) is a Chinese biotechnology company and contract development and manufacturing organization (CDMO) founded in 2016. The company specializes in process development, cell line development, and commercial-scale GMP manufacturing of biologics, particularly monoclonal antibodies and recombinant proteins. Its therapeutic pipeline includes a humanized anti-EGFR monoclonal antibody (HL07) developed in collaboration with Hualan Biological Engineering, which is currently in Phase 2 clinical trials for colorectal cancer, and a recombinant Exendin-4-Fc fusion protein for metabolic disorders. Shengming Biotechnology operates advanced mammalian cell culture platforms with bioreactor capacities up to 40,000L to support global biopharmaceutical development.